Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A new epithelial cell subpopulation predicts response to surgery, chemotherapy, and immunotherapy in bladder cancer

ABSTRACT: A new epithelial cell subpopulation predicts response to surgery, chemotherapy, and immunotherapy in bladder cancer

PROVIDER: PRJNA719160 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14131952.fastq.gz	Fastqsanger.gz
	SRR14131953.fastq.gz	Fastqsanger.gz
	SRR14131954.fastq.gz	Fastqsanger.gz
	SRR14131955.fastq.gz	Fastqsanger.gz
	SRR14131956.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

A new epithelial cell subpopulation predicts response to surgery, chemotherapy, and immunotherapy in bladder cancer

Project description:A new epithelial cell subpopulation predicts response to surgery, chemotherapy, and immunotherapy in bladder cancer

| PRJNA716349 | ENA

A new epithelial cell subpopulation predicts response to surgery, chemotherapy, and immunotherapy in bladder cancer

Project description:The advent of neoadjuvant chemotherapy (NAC) prior to surgery and immune checkpoint therapy (ICT) have revolutionized bladder cancer management1-7. However, stratification of patients that would benefit most from these modalities remains a major clinical challenge. Here, we combine single nuclei RNA sequencing with spatial transcriptomics and single cell resolution spatial proteomic analysis of human bladder cancer to identify a novel epithelial subpopulation with therapeutic response prediction ability. These cells were defined by expression of Cadherin 12 (CDH12, N-Cadherin 2), catenins and other epithelial markers. CDH12-enriched tumors define patients with poor outcome following surgery with or without NAC. In contrast, CDH12-enriched tumors had a superior response to ICT. In all settings, patient stratification by tumor CDH12 enrichment offered better prediction of outcome than currently established bladder cancer subtypes. Molecularly, the CDH12 population resembles an undifferentiated state with inherent chemoresistance mediated through ALDH1A1 expression and fibroblast activation potential. Furthermore, CDH12-enriched cells express PD-L1 and PD-L2 and co-localize with exhausted T-cells, possibly mediated through CD49a (ITGA1), providing one explanation for ICT efficacy in these tumors. Altogether, this study describes a new cancer cell population with an intriguing diametric response to the major therapeutic modalities in bladder cancer. Importantly, it also provides a compelling rationale for the design of novel biomarker guided therapeutic clinical trials.

2021-06-04 | GSE171351 | GEO

A new epithelial cell subpopulation predicts response to surgery, chemotherapy, and immunotherapy in bladder cancer

2021-06-04 | GSE169379 | GEO

An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer.

Project description:Neoadjuvant chemotherapy (NAC) prior to surgery and immune checkpoint therapy (ICT) have revolutionized bladder cancer management. However, stratification of patients that would benefit most from these modalities remains a major clinical challenge. Here, we combine single nuclei RNA sequencing with spatial transcriptomics and single-cell resolution spatial proteomic analysis of human bladder cancer to identify an epithelial subpopulation with therapeutic response prediction ability. These cells express Cadherin 12 (CDH12, N-Cadherin 2), catenins, and other epithelial markers. CDH12-enriched tumors define patients with poor outcome following surgery with or without NAC. In contrast, CDH12-enriched tumors exhibit superior response to ICT. In all settings, patient stratification by tumor CDH12 enrichment offers better prediction of outcome than currently established bladder cancer subtypes. Molecularly, the CDH12 population resembles an undifferentiated state with inherently aggressive biology including chemoresistance, likely mediated through progenitor-like gene expression and fibroblast activation. CDH12-enriched cells express PD-L1 and PD-L2 and co-localize with exhausted T-cells, possibly mediated through CD49a (ITGA1), providing one explanation for ICT efficacy in these tumors. Altogether, this study describes a cancer cell population with an intriguing diametric response to major bladder cancer therapeutics. Importantly, it also provides a compelling framework for designing biomarker-guided clinical trials.

| S-EPMC8361097 | biostudies-literature

Transcription profiling of human ovarian tumors (43) from untreated patients prior to surgery vs. chemotherapy treated prior to surgery

Project description:Gene expression profiles of malignant carcinomas surgically removed from ovarian cancer patients pre-treated with chemotherapy (neo-adjuvant) prior to surgery group into two distinct clusters. One group clusters with carcinomas from patients not pre-treated with chemotherapy prior to surgery (C-L) while the other clusters with non-malignant adenomas (A-L). Although the C-L cluster is preferentially associated with p53 loss-of-function (LOF) mutations, the C-L cluster cancer patients display a more favorable clinical response to chemotherapy as evidenced by enhanced long-term survivorships. Experiment Overall Design: A set of 43 ovarian tumors was obtained from the Ovarian Cancer Institute (Atlanta). Tissue was collected at the time of surgery and preserved in RNAlater (Ambion, Austin, TX) within one minute of collection. Labeled probe was hybridized to the Affymetrix HG-U95Av2 arrays.

2008-11-22 | E-GEOD-7463 | biostudies-arrayexpress

An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer

Project description:An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer

| PRJNA1052123 | ENA

An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer [RNA-Seq]

Project description:Individual cancers are composed of heterogeneous tumor cells with distinct phenotypes and genotypes, with triple negative breast cancers (TNBC) demonstrating the most heterogeneity among breast cancer types. Variability in transcriptional phenotypes could meaningfully limit the efficacy of monotherapies and fuel drug resistance, although to an unknown extent. To determine if transcriptional differences between tumor cells lead to differential drug responses we performed single cell RNA-seq on cell line and PDX models of breast cancer revealing cell subpopulations in states associated with resistance to standard-of-care therapies. We found that TNBC models contained a subpopulation in an inflamed cellular state, often also present in human breast cancer samples. Inflamed cells display evidence of heightened cGAS/STING signaling which we demonstrate is sufficient to cause tumor cell resistance to chemotherapy. Accordingly, inflamed cells were enriched in human tumors taken after neoadjuvant chemotherapy and associated with early recurrence, highlighting the potential for diverse tumor cell states to promote drug resistance.

2023-12-18 | GSE250157 | GEO

An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer [scRNA-Seq]

2023-12-18 | GSE250156 | GEO

TP53 signature predicts survival outcome in triple-negative breast cancer with neoadjuvant chemotherapy

Project description:TP53 signature predicts survival outcome in triple-negative breast cancer with neoadjuvant chemotherapy

| PRJNA786568 | ENA

An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer [scRNA-Seq]

Project description:An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer [scRNA-Seq]

| PRJNA1052126 | ENA